Citrus Health Group Acquires The Medicine Group

Why It Matters

The move strengthens Citrus' position in the competitive medical communications market, giving pharma companies a more integrated partner for launching CNS therapies and improving patient access to innovative treatments.

Key Takeaways

• Citrus adds CNS expertise via The Medicine Group acquisition
• The Medicine Group brings 13 years of CNS communication experience
• Philip Sjostedt stays on as consultant and executive team member
• Expanded services aim to improve drug launch success and patient access

Pulse Analysis

The medical communications sector has seen a wave of consolidation as agencies seek to offer end‑to‑end solutions for increasingly complex drug development pipelines. Citrus Health Group, known for its evidence‑centric approach, leveraged its partnership with NaviMed Capital to absorb The Medicine Group, a boutique firm with a decade‑plus track record in central nervous system (CNS) therapeutic messaging. This acquisition aligns with a broader industry trend where life‑science companies demand integrated strategies that combine scientific rigor, regulatory insight, and compelling storytelling to differentiate products in crowded therapeutic areas.

For CNS drug developers, communicating robust clinical data is a critical hurdle. The Medicine Group’s expertise in publication planning, medical writing, and stakeholder engagement complements Citrus' existing oncology and rare‑disease capabilities, creating a unified platform that can shepherd a product from early‑stage data generation through launch. By retaining founder Philip Sjostedt as a consultant and executive team member, Citrus ensures continuity of relationships and preserves the nuanced expertise that clients rely on to translate complex trial outcomes into clear, actionable messages for physicians, payers, and patients.

From a market perspective, the expanded service portfolio positions Citrus to capture a larger share of the high‑value CNS market, where launch success rates remain modest and payer scrutiny is intense. The combined entity can now offer comprehensive evidence‑generation strategies, real‑world data integration, and multi‑channel communication plans that accelerate market access and improve patient outcomes. As pharmaceutical firms continue to prioritize value‑based narratives, Citrus' enhanced capabilities are likely to become a differentiator in securing favorable formulary placements and driving adoption of next‑generation CNS therapies.

Deal Summary

Citrus Health Group, Inc., together with NaviMed Capital, announced the acquisition of The Medicine Group, a medical communications agency specializing in CNS disorders. The deal expands Citrus's expertise in CNS, oncology, and rare diseases, with founder Philip Sjostedt remaining as a consultant. Financial terms were not disclosed.